Cambridge Healthtech Institute’s Twelfth Annual

Molecular Diagnostics

Executive Strategies for Success
The Industry Leader’s Networking Event

February 16-18, 2015 | Moscone North Convention Center | San Francisco, CA
Part of the 22nd Annual Molecular Medicine Tri-Conference

 

The growth in the diagnostics sector and personalized therapy is being driven by opportunities in molecular diagnostics. Today, hospitals and healthcare providers need to stay competitive by taking on large-scale projects to match patients with targeted therapy using next generation sequencing and molecular profiling tools. This conference will feature experts on business strategy, platform development, regulation and reimbursement who will outline the steps needed to take to achieve commercial success in the current environment.

Scientific Advisory Board

Alan B. Carter, President, MDx Consulting
Dalia Cohen, Ph.D., Head, Research, Beryllium


PLENARY KEYNOTE SESSION

Panel Discussion: Value of Clinical Utility

Moderator: Elaine Lyon, Ph.D., Medical Director, Molecular Genetics, ARUP
Panelists to be Announced

PANEL DISCUSSION: GENERATING AND COMMUNICATING EVIDENCE FOR PAYER COVERAGE

Moderator: John W. Hanna, Senior Director, Policy & Reimbursement, Veracyte

Medical policy is a complex multi-factor decision-making process. In addition to the objective assessment of medical evidence, plans may consider input from their network providers, employers, patients, and their peers. However, labs can be challenged with getting their medical evidence in front of medical policy review committees and decision makers. Obtaining medical policy coverage requires convincing data, but it also requires active participation of other influencers that drive medical policy review and decision making. This session will discuss how to harness some of those influencers in the medical policy review process.

  • Harnessing local providers and KOLs
  • Empowering patients to advocate for coverage
  • Formally communicating medical evidence to medical policy committees

Panelists:
Robin Harper Cowie, Director, Reimbursement, Biodesix, Inc.
Jerry Conway, Vice President, Reimbursement & Payer Strategy, Foundation Medicine, Inc.
Pam Baker, Senior Director, Market Access, Sales Strategy & Ops, CardioDx Inc.

2015 Is Here! Reimbursement Lessons for Another Year

Rina Wolf, Vice President, Commercialization Strategies, Consulting and Industry Affairs, XIFIN, Inc.

This session will highlight any updates on PAMA, Medicare and commercial payer trends in coverage and pricing, and what labs should be looking out for this year, and beyond.


NEW INSIGHTS INTO DISEASE FROM NON-CODING RNA

Long Noncoding RNA in Neuroblastoma: New Light on the (Old) N-Myc Story

George Calin, M.D., Ph.D., Professor, Experimental Therapeutics, MD Anderson Cancer Center

Journeys through Space and Time: Ultra High-Resolution Expression Profiling of Long Noncoding RNAs

Marcel E. Dinger, Ph.D., Head, Clinical Genomics, Kinghorn Center for Clinical Informatics, Garvin Institute of Medical Research

Talk Title to be Announced

Muller Fabbri, M.D., Ph.D., Saint Baldrick’s Foundation Scholar and Assistant Professor, Pediatrics and Molecular Microbiology & Immunology, University of Southern California- Keck School of Medicine, Norris Comprehensive Cancer Center, Children’s Center for Cancer and Blood Diseases, Children's Hospital Los Angeles


PANEL DISCUSSION: MOLECULAR DIAGNOSTIC TESTS IMPROVE PATIENT CARE AND SAVE COSTS

Moderator: Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

  • What are the new tests?
  • Why are they important?
  • How are they transforming care?
  • Do they save money?
  • Current obstacles to medical adoption

Panelist:
Mark Monane, M.D., MS, Chief Medical Officer, CardioDx, Inc.

PANEL DISCUSSION: SWIMMING WITH THE SHARKS: EVALUATING START-UPS WITH FUNDERS, USERS AND PAYERS 

Moderator: Alan B. Carter, President, MDx Consulting

Is your company ready to take the challenge? Join us for a unique session where seasoned experts will provide candid clinical impact feedback. Start-up companies are encouraged to enter and compete to be chosen for a longer presentation in front of a panel of judges. The first place winner will receive free attendance at an “‘Evidence Based Selling” course sponsored by Sales Performance International (SPI), a $15,000 value. SPI is recognized as one of the top 100 data analytics companies worldwide. Second place winner will receive a $5,000 value for services from SPI.

Applicants will be selected from a pool with product ideas for the molecular diagnostics industry for Assays, Reagents, Platforms, Computation and Data.

Qualifying Criteria:

Start-up companies will be judged on 3 criteria:
     1) Clinical Utility
     2) Investor readiness
     3) Healthcare impact

Format:

  • 15 companies will give 5-minute presentations in the morning session
  • 5 will be chosen to give 10-minute presentation in the afternoon session
  • Summary and Award for top start-ups, first and second place, will be presented by panel of judges

Panel of Judges:

Mark Boguski, M.D., Ph.D., Founder & CMO, Genome Health Solutions
Paul D. Grossman, Ph.D., Venture Partner, Telegraph Hill Partners
Stan Rose, Ph.D., CEO, Transplant Genomics
Enrico Picozza, MS, Venture Partner, HLM Venture Partners
Arun Ganguly, Managing Director, The Ganguly Group

Click Here to Learn More 

PANEL DISCUSSION: WHAT DO YOU HAVE TO DO TO GET A TEST COVERED AROUND HERE?

Insights from Proponents, Payers, and the PMC

Moderator: Lon Castle, M.D., Medical Director, Managed Care, Medical Affairs, CardioDx

Diagnostic companies, health systems, and payers have all been impacted in different ways by the advent of genomics. Their views on how to best incorporate these emerging tests stem from their unique roles within the healthcare system. Insights on how they assess whether a test provides enough value to include it as a covered benefit for their members will be explored. The metrics for getting a molecular diagnostic test covered continue to evolve. Hearing from payers on how they evaluate tests and what factors are most important in demonstrating value will provide good insights into the process for the conference attendees.

  • Determine how health systems evaluate data to determine benefits of a genomic test
  • Appreciate the key elements that determine success (or failure) when creating new genomic tests
  • Understand how payers think about the inclusion of new genomic tests into the medical benefit
  • Hear how organizations such as the Personalized Medicine Coalition are working to guide diagnostic companies in their evidence development process

Panelists:
Charles Stemple, DO, MBS, Corporate Medical Director, Commercial Clinical Policy, Humana
Sherrie Smalley, M.D., Chief, Medical Policy & Benefits Branch, UPMC Health Plan



Discovery, Development and Commercialization of Multiplex Diagnostics

Austin Tanney, Ph.D.,  Marketing Manager, Almac Discovery and Diagnostics, Almac

 


Additional Presentation Sponsored by


Additional Presentation Sponsored by


Additional Presentation Sponsored by


Additional Presentation Sponsored by             



For more details on the conference, please contact:
Christina Lingham
Executive Director, Conferences
Cambridge Healthtech Institute
T: 781-972-5464
E: clingham@healthtech.com 

For partnering and sponsorship information, please contact:
Jon Stroup (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com 

Joseph Vacca (Companies L-Z) 
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781.972.5431
E: jvacca@healthtech.com
 

 

  2015 Plenary Sessions 

2015 MMTC Prelim Agenda 

Premier Sponsors:

Elsevier 


Jackson Laboratory - small logo 

Leica Biosystems 
 

 NanoString2   

 

Singulex 

Thomson Reuters-Large 



Local Partners:

BayBio 


Cabs 


City of SSF